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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.12.003Eosinophilic fasciitis (EF) is a rare disease with characteristic clinical and histological features, previously
reported to be associated with various hematological and solid malignancies. We report a typical case of
eosinophilic fasciitis in a 67-year-old man in association with myelodysplastic syndromes (MDS)/acute myeloid
leukemia (AML) and subsequently bladder cancer. On the two occasions, the eosinophilic fasciitis completely
resolved upon successful treatment of the concomitant malignancy. The diagnosis of EF should trigger further
evaluation for any associated hematological disorder, which, if adequately treated, can result in the resolution
of EF.A67-year-old man initially presented in 2006with progressive fatigue, generalized musclestiffness and diffuse skin induration of the
abdomen and all extremities but sparing the hands
and ﬁngers. His complete blood count was consistent
with mild pancytopenia. There was no eosinophilia,
percentage of peripheral eosinophils was 0.2%,
erythrocyte sedimentation rate (ESR) was elevated
at 115 mm/h, and polyclonal paraproteinemia was
present: IgG was 2034 mg/dl, IGA 576 mg/dl. A full
thickness biopsy of the skin showed inﬁltration of the
deep fascia and the subcutis with lymphocytes, plasma
cells, histiocytes and eosinophils, ﬁndings consistent
with the diagnosis of eosinophilic fasciitis (EF)
(Fig. 1a and b). He was treated with glucocorticoster-
oids, which he received for a total period of one year
with complete resolution of his constitutional and
cutaneous symptoms. However, the pancytopenia
persisted. In October of 2009, he developed a ﬂare-
up of his skin condition accompanied by progressive
pancytopenia. A bone marrow trephine biopsy
showed a hypercellular marrow, trilineage dysplasia,
25% myeloid blasts and a normal karyotype consistent
with acute myeloid leukemia with underlying myelo-
dysplastic syndrome. The patient achieved a complete
hematologic remission after one cycle of induction
chemotherapy with cytarabine and daunorubicin. HeHemawas maintained on prednisone 20 mg daily with com-
plete resolution of his skin induration. Subsequently,
he underwent a non-myloablative double cord alloge-
neic hematopoietic stem cell transplant (dUCT).The
transplant course was complicated by cyclophospha-
mide-induced hemorrhagic cystitis that was treated
with aggressive hydration and platelet transfusion
support. Neutrophils and platelets were engrafted by
days 26 and 42, respectively. A post-transplant bone
marrow biopsy showed full maturation of the myeloid
and erythroid cell lines and no increased number of
blasts. Chimerism studies on day 90 revealed a
100% donor chimerism in both CD3 and CD33 cell
lines. On day 90 post-transplant, the patient devel-
oped a diffuse maculopapular skin rash involving the
abdomen and all extremities and sparing the hands.
A repeat skin biopsy was consistent with ﬂare up of
EF (Fig. 1c and e). Interestingly, this coincided with
painless hematurea. Upon further evaluation, the
patient was diagnosed with high-grade bladder cancer
with invasion into the muscularis propria. He
underwent a robotic-assisted radical cystectomy and
ileal conduit urinary diversion with complete
resolution of the skin indurations without glucocorti-
costeroid use. Three months later, a diagnosis of
metastatic bladder cancer was made, and the patient
elected hospice care.tol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.com
Fig. 1. (A and B) A full thickness biopsy of the skin revealing a striking sclerosing and inflammatory reaction largely concentrated within the deep fascia extending into
muscle. There is replacement of the interstitial spaces of the fascia with sclerotic widened bundles of collagen. In addition, there is supervening inflammation comprising
lymphocytes and plasma cells. In contrast with the peripheral blood eosinophilia, there is a paucity of eosinophils. Attendant myocyte atrophy is also apparent. (C and E) A
skin biopsy performed three years later showing sclerodermoid reaction involving the dermis and the interlobular septa of the fat. The collagen bundles were of wider caliber
with a marked diminution in the interstitial spaces. There was profound adnexal atrophy with only the residual of a few pilar erector muscles and one or two follicles. The
eccrine coil showed loss of the adventitial dermis with some duct ectasia ductular dropout.
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Eosinophilic fasciitis (EF) is a systemic inﬂammatory
disease characterized by myalgia, soft tissue swelling,
skin induration, peripheral eosinophilia, hyper gamma-
globulinemia, and elevated erythrocyte sedimentation
rate. First described in 1974 by Shulman et al.,1 EF is
a connective tissue disorder that appears to be a
variant of scleroderma. Sclerodermatous changes
mainly occur in the skin of the upper extremities and
trunk, usually sparing the hands and ﬁngers, making
the skin hard, wrinkled and tightly bound to the
underlying fascia. In contrast to scleroderma,
Raynaud’s phenomenon, telangiectasias and extra-
cutaneous manifestations are usually absent. Peripheral
blood eosinophilia occurs in 63–93% of patients, hyper
gammaglobulinemia in over 50% and elevated ESR in
26–63%. Lymphocytes, plasma cells and eosinophils
typically inﬁltrate the subcutaneous and fascial tissues,
followed by ﬁbrosis of the interlobular septa.2–6
Since 1978, several reports have appeared linking
EF with various benign and malignant hematologicHematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.codisorders. In the largest case series from Mayo Clinic,
the incidence of associated hematological disease ap-
proached 10%.7 Aplastic anemia seems to be the most
commonly reported hematologic disorder associated
with EF.8–10 EF was also reported to be associated
with thrombocytopenic purpura, myelodysplastic syn-
drome, myeloproliferative disorder, multiple myelo-
ma, Hodgkin’s disease, peripheral T cell lymphoma,
chronic lymphocytic leukemia and myelomonocytic
leukemia.11–21 There are scarce reports linking EF
with solid malignancies. These include prostate can-
cer, choroidal melanoma, lung cancer, and a case of
breast cancer in which EF resolved following mastec-
tomy.7,22–24 Only three cases of EF following alloge-
neic hematopoetic stem cell transplant (HSCT)
have been reported. In one case, it was considered a
rare form of graft versus host disease.25,26
The mechanisms linking diffuse eosinophilic
fasciitis with hematological disorders are unknown.
The question whether EF represents a paraneoplastic
phenomena or whether it serves as the initial trigger
for the concurrent hematologic condition remainsm 91
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essentially unanswered. The role of IL-5 induced
eosinophil proliferation was hypothesized in a patient
with EF-associated T cell lymphoma.27 Hoffman et al.
reported that an IgG serum factor from a patient with
aplastic anemia associated with eosinophilic fasciitis
inhibited CFU-GM, BFU-E and CFU-E derived col-
onies from the normal bone marrow.8 In some pa-
tients with EF, the serum inhibitor produced as the
result of altered immune regulation suppresses the
differentiation of hemopoietic stem cells.9
Corticosteroids remain the mainstay treatment for
EF. However, the addition or switching to immuno-
suppressive drugs (ISD) might be required in steroid
refractory or dependent patients. In a study by Lebe-
aux et al., 44% of patients required the use of ISD.14
Predictors of poor outcome in the same study in-
cluded delay in initiating therapy more than six
months, morphea-like lesions, trunk involvement
and not using methylprednisolone pulses at treatment
initiation.14 Another study linked the association with
hematologic malignancies to a worse prognosis.12HemaOur case has unique features that are worth
reporting. The ﬁrst is the striking presentation of
EF as a paraneoplastic syndrome predating MDS,
AML, and bladder cancer. Another unique feature
of our case is the resolution of skin manifestations
with effective treatment of the primary malignancy,
an observation that lends further support to the view-
point that EF is not the primary event but rather a
secondary phenomenon to the associated malignant
condition. Moreover, to the best of our knowledge,
this is the ﬁrst reported case of a successful
double cord allogeneic stem cell transplant in a
patient with EF associated with MDS/AML. We
feel that it is important to evaluate all patients with
EF for an underlying hematologic disorder as dictated
by the associated clinical and hematological
abnormalities.CONFLICT OF INTEREST
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